NBIX vs. YALA
NBIX (Neurocrine Biosciences, Inc.) and YALA (Yalla Group Limited) are both stocks. NBIX operates in Drug Manufacturers - Specialty & Generic (Healthcare), while YALA operates in Software - Application (Technology). Over the past 5 years, NBIX returned 12.34%/yr vs -16.22%/yr for YALA. Their 0.17 correlation means their historical movements had little consistent relationship.
Performance
NBIX vs. YALA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 17.61% return, which is significantly higher than YALA's -22.33% return.
NBIX
- 1D
- -10.08%
- 1M
- -0.58%
- 6M
- 22.59%
- YTD
- 17.61%
- 1Y
- 30.08%
- 3Y*
- 17.27%
- 5Y*
- 12.34%
- 10Y*
- 12.71%
- ALL TIME*
- 9.11%
YALA
- 1D
- 0.19%
- 1M
- -3.75%
- 6M
- -23.55%
- YTD
- -22.33%
- 1Y
- -30.99%
- 3Y*
- -0.97%
- 5Y*
- -16.22%
- 10Y*
- —
- ALL TIME*
- -9.66%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $278.93M | $232.17M | $211.02M | |
| $1.22M | $1.28M | $1.78M |
NBIX vs. YALA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 17.61% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -1.89% |
YALA Yalla Group Limited | -22.33% | 70.94% | -33.77% | 75.14% | -47.84% | -53.18% | 46.97% |
Correlation
The correlation between NBIX and YALA is 0.06, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.06 |
Correlation (3Y) Balances recent behavior with more history. | 0.09 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.16 |
Correlation (All Time) Calculated using the full available price history since Sep 30, 2020 | 0.17 |
The correlation between NBIX and YALA shifts across timeframes, from 0.06 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.
Fundamentals
NBIX:
$16.77B
YALA:
$832.25M
NBIX:
$6.84
YALA:
$0.80
NBIX:
24.39
YALA:
6.78
NBIX:
0.48
YALA:
0.43
NBIX:
5.10
YALA:
2.85
NBIX:
4.35
YALA:
1.14
NBIX:
$3.37B
YALA:
$337.07M
NBIX:
$3.31B
YALA:
$227.87M
NBIX:
$940.50M
YALA:
$124.32M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. YALA — Risk / Return Rank
NBIX
YALA
NBIX vs. YALA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Yalla Group Limited (YALA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | YALA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.79 | ||
| Sortino ratioReturn per unit of downside risk | +2.58 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 0.85 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 1.45 | -0.70 | +2.15 |
| Martin ratioReturn relative to average drawdown | 3.18 | -1.17 | +4.35 |
Loading charts...
Drawdowns
NBIX vs. YALA - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than YALA's maximum drawdown of -92.42%. Use the drawdown chart below to compare losses from any high point for NBIX and YALA.
Loading charts...
Drawdown Indicators
| NBIX | YALA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -92.42% | -4.79% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -44.16% | +23.26% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -44.16% | +1.27% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -77.27% | +34.38% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | — | — |
Current DrawdownCurrent decline from peak | -10.08% | -86.73% | +76.65% |
Average DrawdownAverage peak-to-trough decline | -43.66% | -78.84% | +35.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.47% | 26.51% | -17.04% |
Volatility
NBIX vs. YALA - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 14.12% compared to Yalla Group Limited (YALA) at 7.58%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than YALA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | YALA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.12% | 7.58% | +6.54% |
Volatility (6M)Calculated over the trailing 6-month period | 26.01% | 22.93% | +3.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.74% | 35.56% | -1.82% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.17% | 53.55% | -20.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.18% | 69.75% | -30.57% |
Dividends
NBIX vs. YALA - Dividend Comparison
Neither NBIX nor YALA has paid dividends to shareholders.
Financials
NBIX vs. YALA - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Yalla Group Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. YALA - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a gross profit of 935.80M and revenue of 959.00M. Therefore, the gross margin over that period was 97.6%.
YALA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Yalla Group Limited reported a gross profit of 52.54M and revenue of 79.01M. Therefore, the gross margin over that period was 66.5%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported an operating income of 151.50M and revenue of 959.00M, resulting in an operating margin of 15.8%.
YALA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Yalla Group Limited reported an operating income of 23.46M and revenue of 79.01M, resulting in an operating margin of 29.7%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a net income of 144.40M and revenue of 959.00M, resulting in a net margin of 15.1%.
YALA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Yalla Group Limited reported a net income of 28.94M and revenue of 79.01M, resulting in a net margin of 36.6%.
Frequently Asked Questions
NBIX and YALA have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (14.12%) compared to YALA (7.58%). In terms of maximum drawdown, NBIX dropped -97.21% vs YALA's -92.42%.
NBIX currently has the higher Sharpe Ratio (0.91 vs -0.88), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and YALA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer